S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.21%)
T   16.80 (+1.27%)
F   12.14 (+0.17%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.44 (+0.45%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.21%)
T   16.80 (+1.27%)
F   12.14 (+0.17%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.44 (+0.45%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.21%)
T   16.80 (+1.27%)
F   12.14 (+0.17%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.44 (+0.45%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.21%)
T   16.80 (+1.27%)
F   12.14 (+0.17%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.44 (+0.45%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)

Foghorn Therapeutics (FHTX) Stock Price, News & Analysis

$5.98
-0.11 (-1.81%)
(As of 04:00 PM ET)
Today's Range
$5.88
$6.51
50-Day Range
$2.82
$6.81
52-Week Range
$2.70
$9.97
Volume
119,316 shs
Average Volume
210,234 shs
Market Capitalization
$252.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.83

Foghorn Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
149.3% Upside
$14.83 Price Target
Short Interest
Bearish
6.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.45) to ($2.16) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.13 out of 5 stars

Medical Sector

584th out of 939 stocks

Pharmaceutical Preparations Industry

274th out of 439 stocks


FHTX stock logo

About Foghorn Therapeutics Stock (NASDAQ:FHTX)

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

FHTX Stock Price History

FHTX Stock News Headlines

Foghorn Therapeutics Inc (FHTX)
AI Stock Caught Trading Under Secret Name
We have uncovered perhaps the most unusual AI stock we've ever seen.It's expected to see massive revenue this year - $215 billion.  The company holds over 29,000 patents in the U.S. It pays an enormous dividend.
AI Stock Caught Trading Under Secret Name
We have uncovered perhaps the most unusual AI stock we've ever seen.It's expected to see massive revenue this year - $215 billion.  The company holds over 29,000 patents in the U.S. It pays an enormous dividend.
Foghorn Therapeutics Announces CFO Departure
Foghorn Therapeutics Inc Ordinary Shares FHTX
FHTX Nov 2023 5.000 call
See More Headlines
Receive FHTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Foghorn Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/08/2023
Today
2/23/2024
Next Earnings (Estimated)
3/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FHTX
Fax
N/A
Employees
161
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.83
High Stock Price Target
$20.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+149.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-108,880,000.00
Net Margins
-316.87%
Pretax Margin
-310.00%

Debt

Sales & Book Value

Annual Sales
$19.23 million

Miscellaneous

Free Float
38,320,000
Market Cap
$251.21 million
Optionable
Optionable
Beta
2.65
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Adrian H. B. Gottschalk (Age 48)
    President, CEO & Director
    Comp: $790.62k
  • Dr. Steven F. Bellon Ph.D. (Age 59)
    Chief Scientific Officer
    Comp: $565.5k
  • Mr. Michael J. LaCascia (Age 59)
    Chief Legal Officer
    Comp: $565.5k
  • Dr. Gerald R. Crabtree M.d.
    Founder & Member of Scientific Advisory Board
  • Mr. Stephen J. DiPalma (Age 65)
    Treasurer & Interim CFO
  • Mr. Saurabh Sewak Ph.D.
    Vice President of Corporate Development
  • Mr. Carlos Costa (Age 51)
    Chief People Officer
  • Ms. Fanny Cavalie (Age 46)
    Chief Strategy & Business Operations Officer
  • Dr. Alfonso Quintas Cardama M.D. (Age 53)
    Chief Medical Officer














FHTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Foghorn Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Foghorn Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" FHTX shares.
View FHTX analyst ratings
or view top-rated stocks.

What is Foghorn Therapeutics' stock price target for 2024?

4 brokers have issued 1 year price targets for Foghorn Therapeutics' shares. Their FHTX share price targets range from $6.00 to $20.00. On average, they expect the company's share price to reach $14.83 in the next year. This suggests a possible upside of 149.3% from the stock's current price.
View analysts price targets for FHTX
or view top-rated stocks among Wall Street analysts.

How have FHTX shares performed in 2024?

Foghorn Therapeutics' stock was trading at $6.45 at the start of the year. Since then, FHTX stock has decreased by 7.8% and is now trading at $5.95.
View the best growth stocks for 2024 here
.

Are investors shorting Foghorn Therapeutics?

Foghorn Therapeutics saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 1,060,000 shares, an increase of 16.2% from the January 15th total of 912,600 shares. Based on an average daily volume of 137,300 shares, the short-interest ratio is currently 7.7 days. Approximately 6.0% of the company's stock are short sold.
View Foghorn Therapeutics' Short Interest
.

When is Foghorn Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our FHTX earnings forecast
.

How were Foghorn Therapeutics' earnings last quarter?

Foghorn Therapeutics Inc. (NASDAQ:FHTX) posted its earnings results on Monday, May, 8th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.71) by $0.02. The business had revenue of $5.31 million for the quarter, compared to the consensus estimate of $6.09 million.

What ETF holds Foghorn Therapeutics' stock ?

Range Cancer Therapeutics ETF holds 14,641 shares of FHTX stock, representing 1.36% of its portfolio.

When did Foghorn Therapeutics IPO?

(FHTX) raised $120 million in an initial public offering (IPO) on Friday, October 23rd 2020. The company issued 7,500,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Morgan Stanley and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Foghorn Therapeutics' major shareholders?

Foghorn Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Raymond James & Associates (4.90%), Vanguard Group Inc. (2.43%), Point72 Asset Management L.P. (1.28%), Birchview Capital LP (0.76%), Northern Trust Corp (0.47%) and Panagora Asset Management Inc. (0.23%).
View institutional ownership trends
.

How do I buy shares of Foghorn Therapeutics?

Shares of FHTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FHTX) was last updated on 2/23/2024 by MarketBeat.com Staff